Healthcare signals are stable with selective opportunity. GLP-1 obesity drug demand is reshaping insurance and hospital utilisation models. Medical device demand is recovering post-pandemic procedure backlog clearance. US drug pricing reform risk (IRA Medicare negotiation) is a headwind for large-cap pharma but biopharma innovation signals are strong.